Literature DB >> 35991474

Role of transient elastography and APRI in the assessment of pediatric cystic fibrosis liver disease.

Jessica P Woolfson1,2, Richard A Schreiber1,2, Shraavan Raveendran2, Mark Chilvers2,3, Collin Barker1,2, Orlee R Guttman1,2.   

Abstract

Background: Diagnosis and monitoring of cystic fibrosis liver disease (CFLD) is challenging. Transient elastography (TE) is a rapid, non-invasive method for assessing liver fibrosis. Its role in detecting fibrosis in CFLD has only begun to be explored. The aspartate aminotransferase to platelet ratio index (APRI) has been validated as a predictor of hepatic fibrosis in other chronic liver diseases. The purpose of this study was to assess the utility of APRI and TE in identifying liver fibrosis in pediatric CF patients.
Methods: Patients aged 2-18 years were recruited from the British Columbia Children's Hospital CF clinic. Patients were determined to have CFLD using standard criteria. Charts were reviewed, and each patient underwent TE.
Results: Of the 55 patients included in the study (50.9% male, mean age 11.6 y), 22 (40%) had CFLD. All mean liver enzymes were higher in the CFLD group, notably alanine transaminase (p = 0.031). Mean liver stiffness (LS) and APRI were also higher in the CFLD group (LS: 5.9 versus 4.5 kPa, p = 0.015; APRI: 0.40 versus 0.32, p = 0.119). Linear regression showed a mild positive association between the two (r 2 = 0.386). Conclusions: TE values were higher among CFLD patients and correlated with APRI values, suggesting that these tools may have clinical applications for identifying and following this population. Further research is needed on a larger scale to determine the relative value and clinical utility of TE and APRI among patients with CFLD.
Copyright © 2021 Canadian Association for the Study of the Liver.

Entities:  

Keywords:  cystic fibrosis-associated liver disease; liver fibrosis; non-invasive; pediatric Author Affiliation; transient elastography

Year:  2021        PMID: 35991474      PMCID: PMC9203161          DOI: 10.3138/canlivj-2020-0008

Source DB:  PubMed          Journal:  Can Liver J        ISSN: 2561-4444


  41 in total

1.  Natural history of liver disease in cystic fibrosis.

Authors:  A Lindblad; H Glaumann; B Strandvik
Journal:  Hepatology       Date:  1999-11       Impact factor: 17.425

Review 2.  Cystic fibrosis-associated liver disease.

Authors:  Ulrike Herrmann; Gerd Dockter; Frank Lammert
Journal:  Best Pract Res Clin Gastroenterol       Date:  2010-10       Impact factor: 3.043

3.  Aspartate aminotransferase to platelet ratio and fibrosis-4 as biomarkers in biopsy-validated pediatric cystic fibrosis liver disease.

Authors:  Daniel H Leung; Mahjabeen Khan; Charles G Minard; Danielle Guffey; Louise E Ramm; Andrew D Clouston; Gregory Miller; Peter J Lewindon; Ross W Shepherd; Grant A Ramm
Journal:  Hepatology       Date:  2015-09-28       Impact factor: 17.425

4.  Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis.

Authors:  Jaclyn R Stonebraker; Chee Y Ooi; Rhonda G Pace; Harriet Corvol; Michael R Knowles; Peter R Durie; Simon C Ling
Journal:  Clin Gastroenterol Hepatol       Date:  2016-04-05       Impact factor: 11.382

5.  Cystic fibrosis-associated liver disease: a population-based study.

Authors:  Katie Corbett; Suzanne Kelleher; Marion Rowland; Leslie Daly; Brendan Drumm; Gerard Canny; Peter Greally; Roisin Hayes; Billy Bourke
Journal:  J Pediatr       Date:  2004-09       Impact factor: 4.406

6.  Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.

Authors:  Roger Chou; Ngoc Wasson
Journal:  Ann Intern Med       Date:  2013-06-04       Impact factor: 25.391

7.  Comparison of ultrasound and biopsy findings in children with cystic fibrosis related liver disease.

Authors:  Peter R Mueller-Abt; Kieran J Frawley; Ristan M Greer; Peter J Lewindon
Journal:  J Cyst Fibros       Date:  2007-09-27       Impact factor: 5.482

Review 8.  Cirrhosis and other liver disease in cystic fibrosis.

Authors:  Thomas Flass; Michael R Narkewicz
Journal:  J Cyst Fibros       Date:  2012-12-20       Impact factor: 5.482

9.  Serum proteome profiling identifies novel and powerful markers of cystic fibrosis liver disease.

Authors:  Timo Rath; Lisa Hage; Marion Kügler; Katrin Menendez Menendez; Reinhart Zachoval; Lutz Naehrlich; Richard Schulz; Martin Roderfeld; Elke Roeb
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

10.  Analysis of a large cohort of cystic fibrosis patients with severe liver disease indicates lung function decline does not significantly differ from that of the general cystic fibrosis population.

Authors:  Deepika Polineni; Annalisa V Piccorelli; William B Hannah; Sarah N Dalrymple; Rhonda G Pace; Peter R Durie; Simon C Ling; Michael R Knowles; Jaclyn R Stonebraker
Journal:  PLoS One       Date:  2018-10-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.